SG Americas Securities LLC Raises Holdings in Amedisys, Inc. (NASDAQ:AMED)

SG Americas Securities LLC raised its stake in shares of Amedisys, Inc. (NASDAQ:AMEDFree Report) by 2,744.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,553 shares of the health services provider’s stock after acquiring an additional 109,561 shares during the quarter. SG Americas Securities LLC owned approximately 0.35% of Amedisys worth $10,383,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mackenzie Financial Corp grew its holdings in Amedisys by 67.7% in the first quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock worth $164,844,000 after purchasing an additional 386,411 shares during the last quarter. Millennium Management LLC increased its position in Amedisys by 222.6% during the 4th quarter. Millennium Management LLC now owns 478,081 shares of the health services provider’s stock valued at $39,939,000 after buying an additional 329,891 shares in the last quarter. Norges Bank purchased a new stake in Amedisys in the fourth quarter valued at about $26,014,000. Alyeska Investment Group L.P. acquired a new stake in Amedisys in the first quarter worth about $20,775,000. Finally, Deutsche Bank AG grew its stake in shares of Amedisys by 3,024.7% during the fourth quarter. Deutsche Bank AG now owns 273,787 shares of the health services provider’s stock worth $22,872,000 after acquiring an additional 265,025 shares during the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMED has been the subject of a number of recent analyst reports. assumed coverage on shares of Amedisys in a research note on Wednesday. They issued a “buy” rating for the company. Cantor Fitzgerald boosted their price target on Amedisys from $100.00 to $101.00 and gave the company a “neutral” rating in a research note on Thursday. Jefferies Financial Group cut Amedisys from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Credit Suisse Group lowered Amedisys from an “outperform” rating to a “neutral” rating in a research report on Tuesday, June 6th. Finally, Truist Financial raised their price target on shares of Amedisys from $97.00 to $101.00 in a research report on Tuesday, June 27th. Ten analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $109.67.

View Our Latest Research Report on AMED

Amedisys Price Performance

NASDAQ:AMED opened at $93.73 on Friday. The stock has a 50 day moving average price of $92.26 and a 200 day moving average price of $85.39. The stock has a market cap of $3.06 billion, a PE ratio of 1,339.19, a P/E/G ratio of 2.53 and a beta of 1.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.92 and a current ratio of 0.92. Amedisys, Inc. has a one year low of $69.36 and a one year high of $120.85.

Amedisys (NASDAQ:AMEDGet Free Report) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.28. Amedisys had a net margin of 0.10% and a return on equity of 14.00%. The firm had revenue of $552.97 million for the quarter, compared to analysts’ expectations of $568.18 million. During the same quarter in the previous year, the company posted $1.47 EPS. The company’s revenue was down .9% compared to the same quarter last year. Equities research analysts expect that Amedisys, Inc. will post 4.45 EPS for the current fiscal year.

Amedisys Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with's FREE daily email newsletter.